ArticleFrontiers in microbiology2016
Membrane Proteomics Analysis of the
Article in Frontiers in microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 30 citations in OpenAlex.
- Alkylamidobetaines Induced Changes in Multidrug-Resistant, BiofilmingInternational journal of molecular sciences · 2026Article
- Functional characterization ofFrontiers in microbiology · 2026Article
- Antifungal Susceptibility and Resistance-Associated Gene Expression in NosocomialJournal of fungi (Basel, Switzerland) · 2025Article
- Proteomic Strategies on the Management of Phytopathogenic Fungi.Journal of fungi (Basel, Switzerland) · 2025Review
- tRNA hypomodification facilitates 5-fluorocytosine resistance via cross-pathway control system activation in Aspergillus fumigatus.Nucleic acids research · 2025Article
- Temporal transcriptional response ofeLife · 2024Article
- Cross-feeding affects the target of resistance evolution to an antifungal drug.PLoS genetics · 2023Article
- Article
- Genomic evolution towards azole resistance in Candida glabrata clinical isolates unveils the importance of CgHxt4/6/7 in azole accumulation.Communications biology · 2022Article
- Genotypic, proteomic, and phenotypic approaches to decipher the response to caspofungin and calcineurin inhibitors in clinical isolates of echinocandin-resistant Candida glabrata.The Journal of antimicrobial chemotherapy · 2022Article
- What 'Omics can tell us about antifungal adaptation.FEMS yeast research · 2022Review
- Characterization of theJournal of fungi (Basel, Switzerland) · 2022Article
- Prevalence, Genetic Structure, and Antifungal Susceptibility of thePathogens (Basel, Switzerland) · 2021Article
- Role of CgTpo4 in Polyamine and Antimicrobial Peptide Resistance: Determining Virulence inInternational journal of molecular sciences · 2021Article
- Article
- Candida glabrata Transcription Factor Rpn4 Mediates Fluconazole Resistance through Regulation of Ergosterol Biosynthesis and Plasma Membrane Permeability.Antimicrobial agents and chemotherapy · 2020Article
- A homologous overexpression system to study roles of drug transporters in Candida glabrata.FEMS yeast research · 2020Article
- Screening the Drug:HFrontiers in cellular and infection microbiology · 2020Article
- Trichophyton rubrum Azole Resistance Mediated by a New ABC Transporter, TruMDR3.Antimicrobial agents and chemotherapy · 2019Article
- A Transcriptomics Approach To Unveiling the Mechanisms ofAntimicrobial agents and chemotherapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resistance to 5-flucytosine (5-FC), used as an antifungal drug in combination therapy, compromises its therapeutic action. In this work, the response of the human pathogen
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.